EVIO Inc. announced the launch of its EVIO Biosciences Division. EVIO Biosciences will explore combination drug therapeutics through in vitro and clinical research. The new division reflects the growing need for education and broader dissemination of cannabis and cannabinoid biotechnology research in the scientific and medical community, particularly in the face of the widespread changes to cannabis regulation worldwide.

The division will be led by EVIO's Chief Science Officer, Dr. Anthony Smith. This allows EVIO to leverage its scientific and human capital expertise to focus on development of intellectual property and research. The division's goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products to the human endocannabinoid system.